Leerink Partnrs Weighs in on Intra-Cellular Therapies, Inc.’s FY2027 Earnings (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) – Investment analysts at Leerink Partnrs reduced their FY2027 earnings estimates for Intra-Cellular Therapies in a research report issued to clients and investors on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn $5.25 per share for the year, down from their prior estimate of $5.45. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ FY2028 earnings at $6.40 EPS.

ITCI has been the subject of a number of other research reports. Canaccord Genuity Group increased their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. TD Cowen upped their price objective on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Needham & Company LLC upped their price objective on shares of Intra-Cellular Therapies from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, June 18th. JPMorgan Chase & Co. increased their price target on shares of Intra-Cellular Therapies from $75.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, Mizuho increased their price objective on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $94.33.

Check Out Our Latest Report on Intra-Cellular Therapies

Intra-Cellular Therapies Stock Up 4.3 %

Shares of ITCI opened at $77.29 on Thursday. The firm has a 50-day moving average price of $69.05 and a 200 day moving average price of $69.31. The firm has a market capitalization of $8.16 billion, a PE ratio of -66.63 and a beta of 1.01. Intra-Cellular Therapies has a 52-week low of $45.50 and a 52-week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. The business had revenue of $144.90 million during the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The company’s quarterly revenue was up 52.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.46) earnings per share.

Insider Buying and Selling

In related news, Director Rory B. Riggs sold 4,462 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.57, for a total transaction of $337,193.34. Following the transaction, the director now owns 116,600 shares of the company’s stock, valued at $8,811,462. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.57, for a total transaction of $337,193.34. Following the sale, the director now owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nostrand Robert L. Van sold 20,000 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the sale, the director now owns 9,690 shares in the company, valued at approximately $735,567.90. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several institutional investors and hedge funds have recently made changes to their positions in ITCI. Avoro Capital Advisors LLC acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at $161,543,000. Norges Bank acquired a new position in Intra-Cellular Therapies during the 4th quarter worth about $85,744,000. Vanguard Group Inc. raised its holdings in Intra-Cellular Therapies by 6.5% during the 4th quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock worth $651,334,000 after purchasing an additional 554,577 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Intra-Cellular Therapies by 56.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 763,974 shares of the biopharmaceutical company’s stock worth $54,716,000 after purchasing an additional 275,368 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Intra-Cellular Therapies during the 1st quarter worth about $18,379,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

(Get Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Recommended Stories

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.